Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab and Anlotinib in Recurrent or Metastatic Gynecological Cancer
NCT05028504Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab, anlotinib in ovarian cancer, endometrial cancer (EC), Cervical Cancer (CC), sponsored by Sichuan Cancer Hospital. Started May 2022; status: recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05028504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028504.